Ipamorelin
A ghrelin-mimetic growth hormone secretagogue often paired with CJC-1295 in research-market discussions.
Also appears in: Performance
What has the price actually done?
Daily, exact-comparability offers. Discounts use the terms known on each historical date.
How this history is calculated
Effective price per mg uses an active dated override first, then the row-level historical discount, then the vendor default from the same Git revision. Aggregate chart points include exact-comparability offers only. Missing observations remain gaps; the series does not interpolate across unavailable offers or absent snapshots.
Let the market come to you.
Watch the best market price or one vendor. Get one email when Ipamorelin crosses your target, drops, or sets a new tracked low—without daily noise.
This name primarily lives in the research market and should not be read like an approved pharmaceutical product.
Primary research area: GH axis. Also surfaces under Performance for browsing and discovery.
No major aliases are tracked for this profile yet.
No FDA label signal · 3 trials · 50 PubMed results
Ipamorelin has name-matched human trials with published or reported controlled evidence, but is not FDA-approved. The research is real and ongoing — treat findings as developing rather than settled.
Ipamorelin has 2 name-matched clinical trials (highest phase: Phase 2) and 50 PubMed-indexed publications and is not FDA-approved. Human trials are registered but none have posted results yet.
Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.
Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-09-08 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →
What ipamorelin is
Ipamorelin is a growth hormone secretagogue that is usually discussed as a ghrelin-mimetic peptide. It commonly appears in the same conversations as CJC-1295 because the two are frequently described together in growth-hormone optimization stacks.
Why it matters
It is one of the most recognizable non-approved entries in the growth-hormone peptide category, so it helps anchor the library for readers trying to understand that corner of the market.
Regulatory context
Ipamorelin is not FDA-approved as a peptide medicine in the United States. On PeptideBenchmark it is categorized as research-market, not approved therapy.
Practical reading note
If a page talks about ipamorelin as if it were standard wellness medicine, that is usually a sign the regulatory context is being blurred.